This article is more than 5 years old. Information may no longer be current.

VIDEO: Speaker compares available therapies for BRAF–positive melanoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, discussed how clinicians can decide whether to use immunotherapy or molecularly targeted therapy to treat patients with BRAF–positive melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.

Atkins presented background on treatment with ipilimumab (Yervoy, Bristol Myers Squibb), nivolumab (Opdivo, Bristol Myers Squibb), BRAF inhibitors and combinations of these agents.

“Hopefully the research that we’re doing ... in how to treat patients who don’t respond or become resistant to these various therapies will bring us to where we want to be, which is now, I think, within sight,” he said.